CN1946416A - 用于保护、恢复和增强效应细胞、组织和器官具有延迟的治疗窗口的组织保护性细胞因子 - Google Patents

用于保护、恢复和增强效应细胞、组织和器官具有延迟的治疗窗口的组织保护性细胞因子 Download PDF

Info

Publication number
CN1946416A
CN1946416A CNA2004800208589A CN200480020858A CN1946416A CN 1946416 A CN1946416 A CN 1946416A CN A2004800208589 A CNA2004800208589 A CN A2004800208589A CN 200480020858 A CN200480020858 A CN 200480020858A CN 1946416 A CN1946416 A CN 1946416A
Authority
CN
China
Prior art keywords
cells
erythropoietin
injury
administered
tissue protective
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2004800208589A
Other languages
English (en)
Chinese (zh)
Inventor
A·切拉米
M·布赖恩斯
T·科尔曼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
H Lundbeck AS
KENNETH S WARREN LABORATORIES
Original Assignee
H Lundbeck AS
KENNETH S WARREN LABORATORIES
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H Lundbeck AS, KENNETH S WARREN LABORATORIES filed Critical H Lundbeck AS
Publication of CN1946416A publication Critical patent/CN1946416A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Virology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Psychology (AREA)
CNA2004800208589A 2003-05-19 2004-05-19 用于保护、恢复和增强效应细胞、组织和器官具有延迟的治疗窗口的组织保护性细胞因子 Pending CN1946416A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47166103P 2003-05-19 2003-05-19
US60/471,661 2003-05-19

Publications (1)

Publication Number Publication Date
CN1946416A true CN1946416A (zh) 2007-04-11

Family

ID=33539032

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2004800208589A Pending CN1946416A (zh) 2003-05-19 2004-05-19 用于保护、恢复和增强效应细胞、组织和器官具有延迟的治疗窗口的组织保护性细胞因子

Country Status (13)

Country Link
US (1) US20090258821A1 (cg-RX-API-DMAC10.html)
EP (1) EP1633305A2 (cg-RX-API-DMAC10.html)
JP (1) JP2007505159A (cg-RX-API-DMAC10.html)
KR (1) KR20060013547A (cg-RX-API-DMAC10.html)
CN (1) CN1946416A (cg-RX-API-DMAC10.html)
BR (1) BRPI0410470A (cg-RX-API-DMAC10.html)
CA (1) CA2526096A1 (cg-RX-API-DMAC10.html)
EA (1) EA200501828A1 (cg-RX-API-DMAC10.html)
IL (1) IL172035A0 (cg-RX-API-DMAC10.html)
IS (1) IS8156A (cg-RX-API-DMAC10.html)
MX (1) MXPA05012515A (cg-RX-API-DMAC10.html)
NO (1) NO20056000L (cg-RX-API-DMAC10.html)
WO (1) WO2004112693A2 (cg-RX-API-DMAC10.html)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030072737A1 (en) * 2000-12-29 2003-04-17 Michael Brines Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs
JP2006521405A (ja) * 2003-03-27 2006-09-21 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 発作回復におけるエリトロポイエチンの使用
US7718363B2 (en) 2003-04-25 2010-05-18 The Kenneth S. Warren Institute, Inc. Tissue protective cytokine receptor complex and assays for identifying tissue protective compounds
JP2008505184A (ja) * 2004-07-02 2008-02-21 ザ ケネス エス．ウォーレン インスティテュート，インコーポレーテッド 完全にカルバミル化されたエリトロポイエチンを生成する方法
EP1781697B1 (en) * 2004-07-07 2009-04-22 H.Lundbeck A/S Novel carbamylated epo and method for its production
US9345745B2 (en) * 2005-04-29 2016-05-24 Bo Wang Methods for treating inflammatory disorders and traumatic brain injury using stabilized non-hematopoietic EPO short peptides
US9585932B2 (en) 2005-04-29 2017-03-07 Peter C. Dowling Use of EPO-derived peptide fragments for the treatment of neurodegenerative disorders
WO2007052154A2 (en) 2005-04-29 2007-05-10 University Of Medicine And Dentistry Of New Jersey Erythropoietin-derived short peptide and its mimics as immuno/inflammatory modulators
US20070072795A1 (en) * 2005-09-28 2007-03-29 Anton Haselbeck Treatment of neurodegenerative disorders
TW201129374A (en) * 2009-10-26 2011-09-01 Lundbeck & Co As H Use of carbamylated erythropoietin for the treatment of Friedreich's ataxia
US9956265B2 (en) * 2011-04-26 2018-05-01 Ajou University Industry-Academic Cooperation Foundation Composition for aiding surgical procedures for treating ischemic vascular diseases
HRP20220519T1 (hr) * 2011-06-24 2022-05-27 Nono Inc. Kombinacijska terapija ishemije
US9241970B2 (en) 2011-12-13 2016-01-26 Nono Inc. Therapy for subarachnoid hemorrhage and ischemia
US10695402B2 (en) * 2017-03-16 2020-06-30 University Of Rochester Erythropoietin for gastrointestinal dysfunction
RU2762892C1 (ru) * 2021-02-18 2021-12-23 Федеральное государственное автономное образовательное учреждение высшего образования "Белгородский государственный национальный исследовательский университет" (НИУ "БелГУ") Способ коррекции микроциркуляторных нарушений сетчатки асиалированным эритропоэтином

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6531121B2 (en) * 2000-12-29 2003-03-11 The Kenneth S. Warren Institute, Inc. Protection and enhancement of erythropoietin-responsive cells, tissues and organs
US20030072737A1 (en) * 2000-12-29 2003-04-17 Michael Brines Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs
US7300915B2 (en) * 2002-06-05 2007-11-27 The Regents Of The University Of California Use of erythropoietin and erythropoietin mimetics for the treatment of neuropathic pain
US20040091961A1 (en) * 2002-11-08 2004-05-13 Evans Glen A. Enhanced variants of erythropoietin and methods of use
JP2006521405A (ja) * 2003-03-27 2006-09-21 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 発作回復におけるエリトロポイエチンの使用

Also Published As

Publication number Publication date
MXPA05012515A (es) 2006-05-25
US20090258821A1 (en) 2009-10-15
WO2004112693A2 (en) 2004-12-29
IS8156A (is) 2005-11-29
IL172035A0 (en) 2009-02-11
WO2004112693A3 (en) 2006-06-29
KR20060013547A (ko) 2006-02-10
CA2526096A1 (en) 2004-12-29
JP2007505159A (ja) 2007-03-08
EA200501828A1 (ru) 2006-08-25
EP1633305A2 (en) 2006-03-15
BRPI0410470A (pt) 2006-06-20
NO20056000L (no) 2006-02-20

Similar Documents

Publication Publication Date Title
EP0309100B1 (en) Use of amylin or CGRP for the treatment of diabetes mellitus
US6531121B2 (en) Protection and enhancement of erythropoietin-responsive cells, tissues and organs
US20090258821A1 (en) Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs with an extended therapeutic window
HK1000934B (en) Use of amylin or cgrp for the treatment of diabetes mellitus
EP3570888A1 (en) Treatment of age-related macular degeneration and other eye diseases with one or more therapeutic agents
EA011586B1 (ru) Новый карбамилированный еро и способ его получения
US20020082215A1 (en) Method for treating ischemic events affecting the central nervous system
WO2006014466A2 (en) Novel carbamylated epo and method for its production
US20250090637A1 (en) Methods of inhibiting cerebral inflammation
US20100113347A1 (en) Exenatide and dalargin-based medicinal preparation for treating pancreatic diabetes
JP2005535607A (ja) サルコイドーシスを治療するための血管作動性腸管ペプチドの生物活性をもつ化合物の使用
CN1897960A (zh) 用于保护、恢复和增强效应细胞、组织和器官具有延迟的治疗窗口的组织保护性细胞因子
CN104707130A (zh) 在cns神经性损伤后非-急性期间处理的组合物及方法
CN1387404A (zh) 治疗肺病的方法和组合物
WO2005039625A1 (en) Growth hormone secretagogue receptor agonists
HK1103014A (en) Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs with an extended therapeutic window
CN1278184A (zh) 预防或治疗局部缺血性疾病的药剂
CN118987212A (zh) 治疗视网膜变性患者炎症和感光细胞变性的组合物与方法
WO2022216617A1 (en) Effect of ghrh antagonists in diabetes and obesity
US20220362219A1 (en) Retina regeneration through epigenetics manipulation
MXPA06000690A (en) Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs with an extended therapeutic window
KR20060084844A (ko) 확장된 치료 윈도우를 갖는, 반응성 세포, 조직 및 기관의보호, 회복 및 개선을 위한 조직 보호성 사이토카인
US20240408077A1 (en) Atm kinase inhibitors for use in the treatment of neurological conditions
WO2024120493A1 (en) Formulation and use of a fusion protein
JP2009504636A (ja) 血漿または血清を含む神経損傷治療用の医薬組成物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication